Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
- Registration Number
- NCT00757341
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SKI-606 SKI-606 -
- Primary Outcome Measures
Name Time Method Mass Balance and Metabolic Disposition 10 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the key metabolites identified in the mass balance study of bosutinib (SKI-606) in healthy subjects?
How does bosutinib's metabolic disposition compare to other tyrosine kinase inhibitors in phase 1 trials?
What adverse events were observed in NCT00757341 and how do they align with bosutinib's safety profile in CML patients?
What molecular mechanisms underlie bosutinib's (SKI-606) activity against BCR-ABL and Src family kinases?
How does the pharmacokinetic profile of [14C]-labeled bosutinib inform dosing strategies for chronic myeloid leukemia treatment?